pre-IPO PHARMA

COMPANY OVERVIEW

Ranok is a privately held biopharmaceutical company that is pioneering CHAMP™, an innovative approach to targeted protein degradation for the discovery and development of novel therapeutics. Our R&D team brings deep biological insight and chemistry expertise to rapidly identify and advance CHAMP™ degraders for a variety of important disease targets, with the goal to create transformative medicines that benefit patients around the world suffering from cancer and other serious diseases.


LOCATION

  • Waltham, MA, USA
  • Hangzhou, , China

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https:// www.ranoktherapeutics.com


    CAREER WEBSITE

    https://www.ranoktherapeutics.com/careers.html


    SOCIAL MEDIA


    INVESTORS

    kaiyuan-capital lapam-capital lc-ventures med-find-capital shanghai-healthcare-capital wu-capital


    PRESS RELEASES


    Aug 24, 2022

    Ranok Therapeutics Announces Initiation of Patient Dosing in a Phase 1/2 Clinical Trial of RNK05047, a First-in-Class BRD4-Targeting CHAMP™ Protein Degrader


    Feb 15, 2022

    Ranok Therapeutics to Present at BMO Biopharma Spotlight Series on Protein Degraders and Other Next Gen Technologies


    Jan 24, 2022

    Ranok Therapeutics Announces U.S. FDA Clearance to Proceed With Its First-in-Human Trial of RNK05047 in Patients With Advanced Solid Tumor Cancers and Lymphomas (CHAMP-1)


    Nov 29, 2021

    Ranok Therapeutics Announces Agreement with Pfizer on Targeted Protein Degradation


    Sep 20, 2021

    Ranok Therapeutics to Present its CHAMP™ Platform at 19th Annual Discovery on Target Conference


    For More Press Releases


    Google Analytics Alternative